Table 1 Patient Characteristics
From: Clinical markers of immunotherapy outcomes in advanced sarcoma
Patient Characteristics, n | |
|---|---|
Number of patients screened | 138 |
Number of patients deemed eligible | 135 |
Sex (Female/Male) (%) | 47/53 |
Median age at ICI start (yrs) | 62 |
Stage 4 | 130 |
Line of Systemic Therapy, n (%) | |
First | 14 (10) |
Second | 36 (27) |
Third line or beyond | 85 (63) |
Histologies (%) | |
Undifferentiated pleomorphic sarcoma (UPS) | 21 (19) |
Leiomyosarcoma (LMS) | 7 (7) |
Liposarcoma (LPS) | 11 (10) |
Other | 69 (64) |
ICI regimen, n (%) | |
Single-agent ICI | 71 (53) |
ICI + combination | 64 (47) |
ICI + combination Breakdown, n (%) | |
ICI + medication | 31 (59) |
ICI + radiation | 7 (15) |
ICI + surgery | 9 (13) |
ICI + multiple | 14 (13) |
Number of Cycles and NLR, n (%) | |
Received 3 or more cycles | 76 (60) |
NLR < 5 (%) | 112 (92) |
NLR ≥ 5 (%) | 10 (8) |